Compare Quest Diagnostics Inc (DGX) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Southern Copper Corp — how do they compare? Quest Diagnostics Inc trades at $205.66 (market cap $22.80B), while Southern Copper Corp trades at $178.67 (market cap $152.16B). The key difference: Southern Copper Corp is far larger — about 6.7× Quest Diagnostics Inc's market cap, and Southern Copper Corp pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| DGX | SCCO | |
|---|---|---|
Market Cap | $22.80B | $152.16B |
Sector | Health | Basic Materials |
52-Week High | $216.02 | $218.85 |
52-Week Low | $166.42 | $90.54 |
Enterprise Value | $28.82B | $154.22B |
Dividend Yield | 1.67% | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Southern Copper (SCCO) trades at $174.53, down 0.74% on the day, with a bearish technical signal and mixed analyst sentiment. The stock shows strong fundamentals, including a 32.3% net income margin and consistent earnings beats, with Q1 2026 EPS of $1.90 exceeding the $1.82 estimate. Revenue grew to $13.42 billion in 2025, and cash flow from operations reached $4.75 billion. Recent corporate actions include a $1.00 dividend and a 1:1.01 stock split effective May 13, 2026.
The outlook for SCCO is supported by robust profitability and growth in the copper sector, driven by AI and infrastructure demand, but risks include high valuation multiples and bearish technical indicators. Analyst consensus is cautious with a $151.58 price target below the current price, indicating potential downside despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
